News Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
10.45 ^USD	-3.69%		-17.39%	-6.70%

Apr. 11	Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	MT
Mar. 22	B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	Apr. 11	MT
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing	Apr. 03	AQ
B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	Mar. 22	MT
Top Midday Decliners	Mar. 20	MT
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results	Mar. 20	AQ
Harrow, Inc. Provides Earnings Guidance for the Year 2024	Mar. 20	CI
Transcript : Harrow, Inc., Q4 2023 Earnings Call, Mar 20, 2024	Mar. 20
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	Mar. 20	MT
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Harrow : Q4-2023 Letter to Stockholders	Mar. 19	PU
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Restore stock falls as weak tech trading drags down annual results	Mar. 14	AN
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results after Market Close on March 19, 2024	Mar. 06	AQ
Harrow Announces New Appointments to its Board of Directors	Jan. 30	AQ
Harrow, Inc. Announces Board of Director Appointments	Jan. 29	CI
Harrow Announces Availability of VEVYE 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 12	AQ
Harrow Health's Eye Treatment Drug Vevye Now Available in US	Jan. 11	MT
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	Jan. 11	CI
Harrow Partners with Leading Healthcare Market Access Technology Platforms	Jan. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Harrow, Inc.

Equities

HROW

US4158581094

Summary

Filters